ASPIRE - A Study to Prevent Infection with a Ring for Extended Use – is a Phase III safety and effectiveness trial of a vaginal ring containing the antiretroviral dapivirine that is expected to be launched at several sites in Africa beginning mid-2012 and enroll about 3,376 women. The dapivirine vaginal ring was developed by the International Partnership for Microbicides.
See
